PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Clinical trials for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) explained in plain language.
Never miss a new study
Get alerted when new PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) trials appear
Sign up with your email to follow new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World check: can new drug free PNH patients from transfusions?
Disease control Not yet recruitingThis study aims to see how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday Italian clinics. It will follow about 50 adult patients for up to two years to see if the treatment helps raise their hemoglobin levels and allows them t…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial targets rare blood disorder in untreated patients
Disease control Not yet recruitingThis study is testing an investigational drug called SLN12140 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have never taken a complement inhibitor medication. The main goal is to see if SLN12140 can safely reduce the destruction of red blood cells, which is the c…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
First human doses given for new PNH pill
Knowledge-focused Not yet recruitingThis is the first time a new oral drug called CMS-D017 is being tested in people. The study aims to check its safety and see how the body processes it in healthy Chinese adult volunteers. It will test single and multiple doses, comparing them to a placebo. The drug is being devel…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC